Understanding the Australian Life Science Ecosystem

Understanding the Australian Life Science Ecosystem

for Early Clinical Development

Tuesday 11 November 2025

Timings: 09:15-10:45

Australia House, Strand, London, WC2B 4LA

Progress towards early development value inflection points is critical to a life science company’s ability to re-finance or secure sought after R&D deals and licensing with Pharma. Australia, with streamlined approval processes and clear R&D tax credit policies has developed an enviable track record of helping companies traverse early development challenges in a timely and cost-effective manner. One Nucleus is keen to ensure our respective members are able to make informed choices about their routes to growth and are delighted to be hosting 360Biolabs and partners in bringing their insights to the UK.

At this event, delegates will learn why Australia is one of the top three destinations for outsourced early phase clinical trials (along with US and China) and why it is reported that conducting a study in AUS vs US (IND required) or EU can save a biotech 6-12 months off their clinical timeline.

Provisional Programme:
09:15 – Registration with Tea/Coffee

09:30 – Welcome

09:40 – The Australia Advantage

10:40 – Close Remarks

10:45 – Close

Speakers:

Angela Luttick
EVP Commercial
360Biolabs, a BioAgilytix Company

Cheryl-Ann Hawkins

Chief Executive Officer

Veritus Research

Louise Moore

Co-Founder and Director

Beyond Drug Development

George Zafiris

Associate

Prime Accounting and Business Advisory

Prices:
Members of One Nucleus, OBN or MedCity: Free
Non-members: £50 +VAT

Please email alicia@onenucleus.com  to register.